Skip to main content

Infosys – a stock to add on every decline

Given the sharp rally, profit booking may be normal. Any reversal in stock price of Infosys is an opportunity to add for the long term

Highlights
• Strong earnings momentum maintained
• Revenue back on growth path
• Multiple operational levers aid strong margin improvement
• Company ups full year revenue and margin guidance
• Record deal win and pipeline exciting

• Profit booking likely after a sharp rally, add on any decline

Infosys (CMP: Rs 1,136, Market Cap: Rs 4,83,912 crore) is close to its 52-week high and the strong Q2 on the top of a strong Q1 amply justifies the run in the stock – up 37 percent in the past three months, matching the IT index return and outperforming the Nifty return of 13 percent by a wide margin.

The second quarter delivered an equally blockbuster performance with healthy traction in revenue, sharp improvement in operating margin, record deal win, robust order pipeline and historic low attrition. Consequently, the company has raised its revenue and margin guidance for the full year. Against this backdrop, how should investors look at Infosys from here on?

We feel the rally in the stock in the past quarter has narrowed the valuation gap with bellwether TCS, but it is still at a discount not only to TCS but many high-quality mid-cap names.  While some profit-taking is likely especially if global markets correct, we would not be a seller in Infosys from a longer term perspective given the tailwind for technology and Infosys’ strong positioning. It is a classic buy-on-dip stock for a long-term portfolio rather than sell-on-rally.

Given Infosys’ stellar Q1, the street was optimistic going into Q2 earnings, and the company delivered results that took even the optimists by surprise.



Source: Company

Key positives

Revenue for the quarter at $3312 million grew by 6.1 percent sequentially in reported, and 4 percent in constant currency. The year-on-year growth is also a positive in reported as well as in constant currency, in contrast to TCS where revenue growth YoY is still negative. For the first half, revenue grew by 1.9 percent YoY in constant currency.




Source: Company

The share of digital rose further in the quarter to 47.3 percent from 44.5 percent of total revenue in the previous quarter, reflecting a strong sequential surge. The YoY growth in digital of 25.4 percent in constant currency, continues to be much ahead of the company’s overall growth rate.

Despite giving 100 percent variable pay to employees and a one-time bonus, operational efficiencies led to a sharp uptick in operating margin by 270 basis points sequentially and 375 basis points YoY to 25.4 percent. Improvement in revenue productivity, uptick in utilisation rate and favourable offshore mix along with reduction in travel expenses aided margins.

Revenue momentum and margin traction has given the management the confidence to raise its full-year guidance. Against last quarter’s expectations of 0 to 2 percent YoY growth in revenue in constant currency, the company now expects full-year revenue to grow by 2 to 3 percent. While some of the margin levers might go away with a salary hike from January 2021 and some travel coming back, riding on strategic levers like a favourable offshore mix, better utilisation of fresher and automation, the company has raised its margin guidance to a new band of 23-24 percent from 21 to 23 percent earlier. The management also alluded to pricing pressure abating significantly.

In terms of geography, the key market of North America (share of 61 percent) grew by a decent 1.9 percent YoY. India, too, showed good momentum on a relatively small base.

Turning to industry verticals, the areas of strength were hitech, life sciences, financial services and retail. Management alluded to momentum coming back in retail, stability coming into manufacturing and strong digital transformation agenda of financial services.

The single-most reason that makes us confident about the company is the momentum in order inflows. Thanks to the deal with Vanguard (of close to $1.5 billion), Infosys had a record deal win in the quarter. Of the 16 large deals it won, 11 were from North America, 4 from Europe and 1 from the rest of the world. The client matrix remains healthy with the company adding 96 new clients in the quarter.



Source: Company

Infosys has started publishing the voluntary attrition rate. The figure stood at an all-time low of 7.8 percent.

Collections remained strong with DSO (days sales outstanding) declining by two days to 69 days.

Growth optimism is being reflected in the strong hiring outlook, with the company adding 16,500 freshers in 2020, and 16,000 in the coming year.

The company is sitting on a healthy cash balance of $4.6 bn, creating enough headroom for inorganic opportunities. Incidentally, in the quarter gone by, the company made three acquisitions -- Guide Vision, Blue Acorn and Kaleidoscope.

Key negatives

Given that the company has delivered 1.9 percent YoY growth in constant currency in the first half, the guidance points to a slightly subdued performance in the second half as Q3 is a quarter impacted by furloughs and Q4 is traditionally a soft quarter for the company.

Verticals like communication, energy and manufacturing are yet to fully recover.

Any second wave of the pandemic could cloud the future outlook of the business.

Read Full Article

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...